Please try another search
For the fiscal year ended 31 December 2021, Arena Pharmaceuticals, Inc. revenues decreased 83% to $54K. Net loss increased 52% to $616.4M. Revenues reflect Royalty revenue decrease from $262K to $0K, Collaboration and other revenue decrease of 5% to $54K. Higher net loss reflects Research and development increase of 33% to $310.3M (expense), Salary And other personal Costs increase of 17% to $75.7M (expense).
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | 0.05 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -153.43 | -194.49 | -144.39 | -131.99 |
Net Income | -155.61 | -196.31 | -146.09 | -118.42 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 784.71 | 901.03 | 1084.66 | 1183.94 |
Total Liabilities | 111.47 | 100.31 | 113.58 | 97.94 |
Total Equity | 673.24 | 800.72 | 971.08 | 1085.99 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -452.02 | -331.52 | -213.83 | -119.99 |
Cash From Investing Activities | 321.4 | 372.32 | 389.7 | 227.11 |
Cash From Financing Activities | 135.41 | 126.28 | 118.82 | 106.39 |
Net Change in Cash | 5.03 | 167.11 | 294.63 | 213.43 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review